Bluebird Bio Inc. (NASDAQ:BLUE)’s share price traded down 5% on Tuesday . The stock traded as low as $53.27 and last traded at $53.51, with a volume of 496,886 shares changing hands. The stock had previously closed at $56.30.

Several equities analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Bluebird Bio from a “hold” rating to a “sell” rating in a report on Monday, May 2nd. Cantor Fitzgerald assumed coverage on shares of Bluebird Bio in a report on Thursday, June 2nd. They issued a “hold” rating and a $42.00 price objective on the stock. Wedbush restated an “outperform” rating and issued a $117.00 price objective on shares of Bluebird Bio in a report on Thursday, May 5th. Piper Jaffray Cos. restated a “buy” rating and issued a $117.00 price objective on shares of Bluebird Bio in a report on Wednesday, May 11th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Bluebird Bio in a report on Thursday, May 5th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the stock. Bluebird Bio has an average rating of “Buy” and a consensus target price of $96.09.

The firm’s market capitalization is $2.05 billion. The firm’s 50-day moving average price is $45.82 and its 200-day moving average price is $45.59.

Bluebird Bio (NASDAQ:BLUE) last released its earnings results on Wednesday, May 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.23) by $0.29. The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $4.50 million. The firm’s revenue for the quarter was down 76.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.76) EPS. On average, analysts forecast that Bluebird Bio Inc. will post ($5.90) EPS for the current year.

In related news, insider David Davidson sold 1,000 shares of the business’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $38.73, for a total value of $38,730.00. Following the transaction, the insider now directly owns 10,600 shares of the company’s stock, valued at approximately $410,538. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Eric Sullivan sold 2,912 shares of the business’s stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $55.01, for a total transaction of $160,189.12. Following the completion of the transaction, the insider now directly owns 4,456 shares in the company, valued at $245,124.56. The disclosure for this sale can be found here.

Several institutional investors recently modified their holdings of the company. Rhumbline Advisers increased its stake in Bluebird Bio by 6.0% in the fourth quarter. Rhumbline Advisers now owns 35,855 shares of the company’s stock valued at $2,303,000 after buying an additional 2,023 shares during the period. Nationwide Fund Advisors increased its stake in Bluebird Bio by 40.8% in the fourth quarter. Nationwide Fund Advisors now owns 40,800 shares of the company’s stock valued at $2,620,000 after buying an additional 11,830 shares during the period. Dimensional Fund Advisors LP increased its stake in Bluebird Bio by 6.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 74,831 shares of the company’s stock valued at $4,806,000 after buying an additional 4,454 shares during the period. California Public Employees Retirement System increased its stake in Bluebird Bio by 157.2% in the fourth quarter. California Public Employees Retirement System now owns 94,400 shares of the company’s stock valued at $6,062,000 after buying an additional 57,700 shares during the period. Finally, Marshall Wace LLP increased its stake in Bluebird Bio by 374.8% in the fourth quarter. Marshall Wace LLP now owns 168,427 shares of the company’s stock valued at $10,816,000 after buying an additional 132,956 shares during the period.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.